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Summary
Striae gravidarum (SG), or stretch marks developing during pregnancy, affect up
to 90% of women. While not medically dangerous, SG can be disfiguring, caus-
ing emotional and psychological distress. However, studies specifically addressing
the prevention of SG, especially during pregnancy, are sparse. Furthermore, the
molecular pathogenesis of SG is unclear and may differ from that of striae from
other causes. Considering these factors, we review topical modalities that have
been used specifically for preventing SG during pregnancy. We identify two
major strategies (end points) addressed by these modalities, namely (i) prevent-
ing the de novo development of SG and (ii) reducing the severity of SG that have
recently developed. We also identify risk factors for the development of SG and
suggest that pregnant women with these risk factors are an appropriate target
population for prevention. In reviewing the literature, we find that there is lim-
ited evidence that centella, and possibly massage with bitter almond oil, may
prevent SG and/or reduce their severity. There is weak evidence that hyaluronic
acid prevents SG. Tretinoin holds promise for reducing the severity of new-onset
SG, but its use is limited by its pregnancy category. Finally, cocoa butter and
olive oil are not effective for preventing SG or reducing the severity of lesions.
We conclude that reliable methods for preventing SG are scarce. Furthermore,
available topical modalities generally lack strong evidence from rigorous, well-
designed, randomized controlled trials with ample numbers of subjects. Thus,
further research is necessary to elucidate SG pathogenesis, which may lead to
effective prevention modalities.
What’s already known about this topic?
• Striae gravidarum (SG), or stretch marks developing during pregnancy, can be dis-
figuring, causing emotional and psychological distress.
• Studies specifically addressing the prevention of SG during pregnancy are sparse.
What does this study add?
• We review topical modalities that have been used specifically for preventing SG
during pregnancy.
• We conclude that reliable methods for preventing SG are scarce, and that topical
modalities generally lack strong evidence from rigorous, well-designed trials with
ample numbers of subjects.
The term striae distensae (SD) refers to stretch marks from
various causes, including pregnancy, weight gain, obesity,
growth spurts and corticosteroid excess.1–3 Striae gravidarum
(SG) are stretch marks specifically developing during
pregnancy. SG affect up to 90% of women.4 They appear in
the second or third trimester, typically on the abdomen and
breasts, and less commonly on the buttocks, hips and thighs.2
Initially, lesions are pink to violaceous and may be oedematous
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or pruritic (striae rubra). Over months to years, the lesions
mature into white, shiny, atrophic, crinkly streaks that are
permanent (striae alba).
Although SG are common, their pathogenesis remains
unclear. Mechanical tension may play a pathogenic role by
damaging dermal connective tissue, as the long axis of lesions
is usually oriented perpendicularly to the direction of greatest
skin stretching.3,5 However, this possibility remains controver-
sial, as increased maternal weight gain during pregnancy,
baseline maternal body mass index and infant birthweight are
not consistently associated with SG development.3,4,6,7
At the molecular level, disruption of dermal connective tis-
sue, including collagen fibrils and elastic fibres, likely leads to
decreased strength and elasticity of lesions.5,8 Indeed, early,
erythematous SG exhibit focal loss and thinning of collagen
bundles.8,9 Variable reduction, thinning and disorganization of
elastic fibres are seen at this stage and may result from elastol-
ysis mediated by infiltrating mast cells and macrophages.6,8–10
Additionally, elastic fibre disorganization may result, in part,
from reduction of fibrillin microfibrils in early SG.9 Increased
hormones during pregnancy, such as glucocorticoids, may
suppress fibroblast production of collagen fibrils and elastic
fibres, thereby hindering complete ‘repair’ of disrupted con-
nective tissue.1,3
In mature SG, the synthetic capacity of fibroblasts remains
reduced, which likely promotes persistence of disrupted con-
nective tissue components and, hence, permanency of
lesions.11 Histologically, mature SG can resemble scars, with
collagen bundles and elastic fibres appearing thin or decreased,
and oriented parallel to the epidermis, which appears atro-
phic.6,8,9,11
While not medically dangerous, SG are disfiguring, causing
emotional and psychological distress.2,12 Thus, women remain
interested in preventing SG and/or reducing their severity.
However, most published studies address the treatment of
established SD from a variety of causes. Studies specifically
addressing the prevention of new-onset SG or reduction of
their severity during pregnancy are sparse. Considering that
the molecular pathogenesis of SG may differ from that of SD
from other causes,13,14 we focus specifically on SG in this
review. Our review differs from recently published ones3 in
that we discuss SG apart from other types of SD and limit our
analysis to topical agents that have been used specifically in
the pregnant population.
Additionally, we identify two major strategies (end points)
for the prevention of SG, namely (i) preventing the de novo
development of SG and (ii) reducing the severity of SG that
have recently developed. To provide clinicians with an evi-
dence-based review aimed at pregnant women, this report dis-
cusses topical modalities with these end points in mind
(Table 1).
Methods
A systematic PubMed and Google Scholar search was per-
formed using the terms ‘striae’, ‘striae gravidarum’, ‘stretch
marks’, ‘pregnancy’, ‘lifestyle’, ‘diet’, ‘exercise’, ‘centella’,
‘Trofolastin’, ‘oil’, ‘cocoa butter’, ‘massage’, ‘hyaluronic acid’,
‘Alphastria’, ‘Verum’ and ‘tretinoin’. Review articles, observa-
tional studies, case series and cohort studies published from
1950 to 2014 were included. Articles published in non-Eng-
lish languages that were able to be translated were included.
The following article types were excluded: conference pro-
ceedings, abstracts, and publications in non-English languages
that were unable to be translated.
Risk factors
An important aspect of SG prevention is predicting their devel-
opment, so that lifestyle modifications or prophylactic thera-
pies can be initiated. Identifying risk factors is central to this
goal, but recognizing those consistently associated with SG
development remains challenging. Pregnant women with one
or more of the attributes listed in Table 2 could be at
increased risk for developing SG and would be an appropriate
target population for prevention strategies.4,14–23
Lifestyle modifications
• Evidence for diet and exercise in preventing SG is lacking.
As indicated in Table 2, increased maternal body mass
index and weight gain during pregnancy may be associated
with SG development. Accordingly, a healthy diet and regular
exercise may play a role in SG prevention. Indeed, some clini-
cians suggest that stretching exercises, such as aerobics, may
be beneficial in this regard. However, there is a lack of data
supporting the efficacy of lifestyle modifications in preventing
SG or reducing their severity during pregnancy. In one study
of 80 nonpregnant individuals, 79% of whom had SD, a 3-
month weight-loss programme did not improve the severity
of lesions, regardless of the intervention (diet alone, diet plus
aerobic exercise, or diet plus resistance exercise).24,25
Topical modalities for preventing striae gravidarum
Centella
• Creams containing centella, a medicinal herb, may be
effective for preventing SG and reducing their severity.
• As centella is often combined with other ingredients, its
specific role in SG prevention requires further investiga-
tion.
Centella asiatica, commonly known as centella, is a plant found
in South Asia that has been studied for treating leprosy, lupus,
venous stasis ulcers and eczema.26 Trofolastin is a proprietary
product containing centella extract, a-tocopherol and colla-
gen–elastin hydrolysates. Another proprietary product contains
centella triterpenes formulated in a cream with
hydroxyprolisilane-C, rosehip oil and vitamin E. While the
mechanism of action of centella is unclear, this ingredient may
stimulate fibroblasts and inhibit glucocorticoid activity.27,28
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Topical application accelerates wound healing and improves
the tensile strength of scars.28 It is possible that centella may
improve SG by similar means, as lesions demonstrate clinical
and histological features that overlap with scars.29
In a randomized, double-blind, placebo-controlled trial
involving 80 women, Mallol et al. showed that daily massage
with Trofolastin cream to the abdomen, breasts, buttocks and
hips from the 12th week of pregnancy until delivery was asso-
ciated with decreased SG incidence.1,30 Whereas 56% (22 of
39) of women in the placebo group developed SG, 34% (14
of 41) in the treatment group developed lesions. The cream
was effective for preventing SG in subjects with a history of
puberty-associated SD, but not in subjects with a history of SG
from preceding pregnancies. In subjects who developed SG,
the cream reduced the severity of lesions, compared with pla-
cebo.
In a randomized, double-blind, placebo-controlled trial,
Garcıa Hernandez et al. enrolled 183 women, who applied the
cream containing centella triterpenes twice a day to the abdo-
men, thighs, hips, buttocks and breasts starting in the 12th
week of pregnancy.31 The incidence of SG was similar
between the treatment and placebo groups (38% vs. 33%,
respectively). However, among women who developed SG,
the severity of lesions remained stable with treatment, while
worsening with placebo. In women without a history of SD,
6% of subjects (one of 17) undergoing treatment developed
SG, compared with 35% (seven of 20) in the control arm.
The authors concluded that the cream reduced the severity of
SG developing during pregnancy, while decreasing the inci-
dence of new SG in women without a history of SD.
Centella is thought to be the active agent in these creams.1
As this ingredient is often combined with others,
well-designed controlled studies are required to determine the
specific efficacy of centella for SG prevention. This ingredient
may not be readily available in certain countries.32 In the
U.S.A. it is available over the counter and potentially costly.
Almond oil
• There is weak evidence that massage with bitter almond
oil may be effective for preventing SG and reducing their
severity.
• Other products containing almond oil have not shown
similar benefit.
Oils have moisturizing properties, and massage may stimu-
late blood flow to the skin.33 It is unclear how the combina-
tion of massage with oils may prevent SG or lessen their
severity. Bitter almond oil has been used for SG because it
reportedly does not pose a risk to the mother and foetus dur-
ing pregnancy.33
In a nonrandomized, comparative study of 141 women
with no history of SG, Timur Tashan and Kafkasli divided sub-
jects into three groups.33 The first group applied bitter almond
oil with a 15-min massage every other day during weeks
19–32 of pregnancy, followed by daily application until deliv-
ery. The second group applied the oil identically without mas-
sage. The third applied nothing. The development of
abdominal SG was significantly reduced in the oil plus mas-
sage group (16 of 47), compared with oil alone (31 of 48)
and the control group (33 of 46). Additionally, if women had
developed SG in the abdominal area, lesions were less severe
in the oil plus massage group. As bitter almond oil alone was
ineffective and massage alone was not studied, further investi-
gation is necessary to clarify which component may be more
beneficial for preventing SG. Other studies discussed here have
suggested that massage, along with emollients/creams, may
be effective for preventing SG.1,34
In a more recent randomized controlled trial, almond oil
was ineffective as part of a proprietary cream (Saj) containing
lanolin, stearin, triethanolamine and bizovax glycerin ami-
dine.35 Soltanipour et al. analysed 150 nulliparous women in
the second trimester and observed no difference in the inci-
dence or severity of abdominal SG between no intervention,
olive oil without massage, or Saj cream without massage (50
subjects in each group). Lesions developed in 60%, 64% and
64% of participants, respectively.
Hyaluronic acid
• There is weak evidence that creams containing hyaluronic
acid, including Alphastria and Verum, can prevent SG.
Alphastria is a proprietary cream containing hyaluronic acid,
allantoin, vitamin A, vitamin E and calcium pantothenate.
Verum is another proprietary cream containing vitamin E,
essential fatty acids, panthenol, hyaluronic acid, elastin and
menthol. The active ingredient in both is hyaluronic acid,
which is thought to improve tensile resistance to mechanical
Table 2 Risk factors potentially associated with development of striae
gravidarum
Maternal factors prior to pregnancy
Family history of striae
Personal history of breast or thigh striae
Young age
Baseline weight
Body mass index > 26
Alcohol intake
Light skin colour
Racea
Maternal factors during pregnancy
Increased weight gain
Increased body mass index at delivery
Increased abdominal and hip girth
Low serum vitamin C level
Low serum relaxin level
Low water intake
Neonatal factors
Increased gestational age at delivery
Increased birthweight
Increased height and head circumference
aDepending on the study, both nonwhite and white race have
been associated with increased risk.
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forces and counteract atrophy by stimulating fibroblast activity
and collagen production to increase skin volume.25 The exact
mechanism of hyaluronic acid in preventing SG is unclear.
Two small studies suggest that hyaluronic acid-containing
compounds may prevent SG during pregnancy. In a double-
blind study involving pregnant women, de Buman et al. dem-
onstrated that Alphastria cream reduced the incidence of SG,
compared with placebo (three of 30 vs. 11 of 30 subjects,
respectively).36
Wierrani et al. enrolled 50 pregnant women at 20 weeks’
gestation, and found that SG developed in 29% (seven of
24) of women who applied Verum to the abdomen, thighs
and breasts with massage, compared with 62% of control
subjects (16 of 26), who performed no massage or topical
application.34 This study was not placebo controlled and
was poorly randomized.30 Parity of participants was also
unclear, making it difficult to ascertain whether participants
had SG from earlier pregnancies.37 Therefore, further inves-
tigation of this preparation for SG prevention is needed,
and the specific effects of the ingredients vs. massage need
clarification.
Tretinoin
• Tretinoin shows promise for decreasing the severity of
erythematous SG.
• Tretinoin is a pregnancy category C drug, and therefore
patients should wait until the postpregnancy/lactation per-
iod to apply it.
Topical tretinoin partially restores decreased collagen forma-
tion in photoaged skin by stimulating the synthetic activity of
dermal fibroblasts. As damage of structural proteins such as
collagen may also occur in SG, topical tretinoin has been stud-
ied for the treatment of this condition. In this context, its
exact mechanisms remain unclear.
Early studies produced conflicting results. In an observa-
tional study by Elson, tretinoin led to ‘significant improve-
ment’ of SD from a variety of causes in 15 of 16 patients.38
In a double-blind, placebo-controlled study by Pribanich et al.,
tretinoin cream 0025% was applied daily for 7 months to
abdominal SG at various stages of development, with six sub-
jects assigned to treatment and five to placebo.39 No improve-
ment occurred with treatment compared with placebo.
More recently, in a double-blind, randomized controlled
study by Kang et al., 22 patients with early (erythematous) SD
from a variety of causes, including pregnancy, applied a higher
strength of tretinoin cream (01%) or vehicle nightly.40 After
6 months, eight of 10 subjects in the tretinoin group demon-
strated marked or definite improvement of lesions, compared
with one of 12 subjects in the vehicle group. Lesions treated
with tretinoin showed a mean decrease in length and width by
14% and 8%, respectively, whereas lesions treated with vehicle
increased by 10% and 24%, respectively. In a small study of 10
subjects by Ash et al., the appearance of mature white SD on the
abdomen or thighs improved with either 20% glycolic acid/
005% tretinoin or 20% glycolic acid/10% L-ascorbic acid.41
Finally, in an open-label, prospective study by Rangel et al., tret-
inoin 01% cream was applied nightly to pregnancy-related
abdominal SG starting 1 week after delivery.42 After 12 weeks
of application, 16 of 20 subjects demonstrated moderate to
marked improvement, and the mean length and width of target
lesions decreased by 20% and 23%, respectively.
Of the studies discussed, only three enrolled subjects with
pregnancy-related SG,39,40,42 and only one examined tretinoin
use specifically for new-onset SD.40 The most common side-
effects in the studies were localized erythema, scaling, itching
and burning, all of which were mild and easily treated with
emollients. Topical tretinoin is a pregnancy category C drug,
and its use during pregnancy and lactation is not generally
recommended.
Cocoa butter
• Studies suggest that cocoa butter, which is often combined
with vitamin E, is not effective for preventing SG or
reducing their severity.
Cocoa butter is a natural fat derived from cocoa beans,
which grow on the tree Theobroma cacao. It is often combined
with vitamin E oil. Some medical providers suggest applying
topical cocoa butter before, during and after pregnancy to pre-
vent SG development.43 Cocoa butter has emollient properties,
although its mechanism of action is not known. Furthermore,
the role of vitamin E in preventing SG is unclear.
In a double-blind, randomized, placebo-controlled trial,
Osman et al. studied 175 nulliparous pregnant women, 91 of
whom applied a lotion containing cocoa butter and vitamin E
daily to the abdomen, breasts and thighs from 12–18 weeks’
gestation until delivery.43 The remaining subjects applied a
placebo lotion lacking cocoa butter and vitamin E. There was
no difference in SG development between the intervention
and control groups. If SG developed, the severity of lesions
was similar between the two groups.
Buchanan et al. conducted a similar randomized, double-
blind, placebo-controlled study in 300 pregnant Afro-
Caribbean women with no previous history of SD.32 Of these
subjects, 150 applied a cream containing 25% cocoa butter
and vitamin E oil daily from 16 weeks’ gestation to delivery,
while the remaining applied a placebo cream. No statistically
significant difference was noticed in the development of SG
between the treatment and placebo groups, with lesions devel-
oping in 44% vs. 55% of subjects, respectively. The interven-
tion cream did not reduce the severity of new SG compared
with placebo.
Olive oil
• Studies suggest that olive oil is not effective for preventing
SG or reducing their severity.
The use of olive oil for preventing SG is popular. Olive oil
is rich in vitamin E and has emollient properties.44
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Early research produced conflicting results. In an observa-
tional study of 116 primagravid women, Poidevin noted that
36 of 50 pregnant women who applied olive oil nightly
developed abdominal SG, compared with 36 of 66 pregnant
women who did not.14 These observations suggested that
olive oil was not effective as prophylaxis for SG development.
In another early observational study, Davey found that the
incidence of SG was reduced by up to 42% in primiparous
women who had used olive oil during pregnancy, compared
with those who did not (26% vs. 68%, respectively).13 The
duration of olive oil use was unclear. These data were
obtained retrospectively from questions asked of 76 women in
the postpartum period and, therefore, are subject to recall
bias.
In a more recent randomized controlled trial, Taavoni et al.
studied the use of olive oil for a short duration in 70 nullipa-
rous pregnant women.45 Participants at 18–20 weeks of gesta-
tion were randomized to no treatment or application of olive
oil to the abdomen without massage twice a day for 8 weeks.
Although the incidence of SG was 46% (16 of 35) in the
intervention group vs. 63% (22 of 35) in the control group,
this difference was not statistically significant. The authors
concluded that initiation of olive oil in the second trimester
did not prevent SG onset.
In the second phase of the same randomized controlled
trial, Soltanipoor et al. followed 100 nulliparous pregnant
women, who applied either nothing or 1 ml of olive oil to
the abdomen without massage twice daily from 18–20 weeks’
gestation until delivery.44 This intervention did not reduce the
incidence or severity of SG. Overall, SG developed in 64% (32
of 50) of the intervention group and 60% (30 of 50) of the
control group.
Recommendations
There is limited evidence that centella and possibly massage
with bitter almond oil may prevent SG and/or reduce the
severity of lesions. There is weak evidence that hyaluronic acid
can prevent SG. Tretinoin holds promise for reducing the
severity of erythematous SG, but its use is limited by its preg-
nancy category. Cocoa butter and olive oil do not demonstrate
efficacy for preventing SG or reducing their severity.
Conclusions
Reliable methods for preventing SG during pregnancy are lack-
ing.30 Compounds that potentially prevent new-onset SG or
reduce their severity lack evidence from rigorous, high-qual-
ity, well-designed, randomized controlled trials with ample
subject numbers.37 Additionally, methods of assessing SG
severity or response to therapy vary considerably among pub-
lished studies (Table 1).
Importantly, SG can cause significant distress.2,12,15 Yet,
major barriers exist to conducting rigorous research on SG
prevention. For instance, the medical and scientific community
remains reluctant to devote substantial research to this
condition, likely because the lesions are not physically harm-
ful. Accordingly, the pathogenesis of SG remains unclear,
hampering the development of rational therapies. The devel-
opment of lesions also remains difficult to predict, hindering
subject recruitment for prospective studies. In this respect,
high-risk groups that tend to develop lesions in predictable
anatomical locations, such as pregnant women, may not only
be a suitable population for SD prevention trials, but also
stand to benefit greatly from positive findings.
Additionally, numerous questions remain regarding the use
of prophylactic agents for SG during pregnancy. For instance,
if a topical agent is initiated for prophylaxis against SG devel-
opment, when should a pregnant woman begin to use it?
How long should she use it? If a topical agent is used to
reduce the severity of recently developed SG, how soon
should treatment commence after lesions have formed? Does
the age of the subject or multiple gestations impact the effi-
cacy of topical agents? Do combinations of the topical agents
discussed above hold promise? What is the safety of various
topical modalities during pregnancy and lactation? Finally,
what is the cost–benefit ratio of preventative therapies used
for SG? These concerns will be important to address in future
studies.
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